Nerve Growth Factor
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Musculoskeletal Pain
Conditions
Musculoskeletal Pain
Trial Timeline
Oct 1, 2017 → Jul 1, 2020
NCT ID
NCT04457466About Nerve Growth Factor
Nerve Growth Factor is a pre-clinical stage product being developed by Lundbeck for Musculoskeletal Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT04457466. Target conditions include Musculoskeletal Pain.
What happened to similar drugs?
1 of 2 similar drugs in Musculoskeletal Pain were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04457466 | Pre-clinical | Terminated |
Competing Products
4 competing products in Musculoskeletal Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride | Eisai | Phase 3 | 40 |
| No intervention | Johnson & Johnson | Pre-clinical | 26 |
| ACE-083 | Merck | Phase 1 | 29 |
| Lumiracoxib | Novartis | Approved | 43 |